[go: up one dir, main page]

BR0215238A - Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas - Google Patents

Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas

Info

Publication number
BR0215238A
BR0215238A BR0215238-0A BR0215238A BR0215238A BR 0215238 A BR0215238 A BR 0215238A BR 0215238 A BR0215238 A BR 0215238A BR 0215238 A BR0215238 A BR 0215238A
Authority
BR
Brazil
Prior art keywords
ophthalmic
optical
drugs
nanoparticles
vehicles
Prior art date
Application number
BR0215238-0A
Other languages
English (en)
Inventor
Howard Allen Ketelson
David L Meadows
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0215238A publication Critical patent/BR0215238A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

"USO DE NANOPARTìCULAS INORGâNICAS SINTéTICAS COMO VEìCULOS PARA DROGAS OFTáLMICAS E óTICAS". A presente invenção refere-se ao uso de nanopartículas de materiais inorgânicos (por exemplo argilas esmectitas sintéticas) em composições farmacêuticas oftálmicas e óticas. As nanopartículas são usadas como veículos biologicamente inertes ou depósitos para drogas oftálmicas e óticas. As nanopartículas podem ser também usadas para modificar as propriedades reológicas das composições , de modo a melhorar a viscosidade ou características de fluxo das composições e/ou aumentar o tempo de retenção das composições no olho ou orelha.
BR0215238-0A 2001-12-21 2002-12-20 Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas BR0215238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34298301P 2001-12-21 2001-12-21
PCT/US2002/041248 WO2003059194A2 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Publications (1)

Publication Number Publication Date
BR0215238A true BR0215238A (pt) 2005-05-31

Family

ID=23344163

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215238-0A BR0215238A (pt) 2001-12-21 2002-12-20 Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas

Country Status (19)

Country Link
US (2) US20050003014A1 (pt)
EP (1) EP1474109B1 (pt)
JP (1) JP2005514429A (pt)
KR (1) KR100990810B1 (pt)
CN (1) CN100441169C (pt)
AT (1) ATE478657T1 (pt)
AU (1) AU2002367029B2 (pt)
BR (1) BR0215238A (pt)
CA (1) CA2467763C (pt)
DE (1) DE60237475D1 (pt)
DK (1) DK1474109T3 (pt)
ES (1) ES2349235T3 (pt)
HK (1) HK1075001A1 (pt)
MX (1) MXPA04004919A (pt)
PL (1) PL211494B1 (pt)
PT (1) PT1474109E (pt)
SI (1) SI1474109T1 (pt)
WO (1) WO2003059194A2 (pt)
ZA (1) ZA200403666B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1474109E (pt) 2001-12-21 2010-10-25 Alcon Inc Utilização de nanopartículas inorgânicas sintéticas como veículos em medicamentos oftálmicos
MXPA04004915A (es) * 2001-12-21 2004-08-11 Alcon Inc Nanoparticulas inorganicas para modificar la viscosidad y las propiedades fisicas de composiciones oftalmicas y oticas.
KR100976291B1 (ko) 2001-12-21 2010-08-16 알콘, 인코퍼레이티드 안과용 조성물중의 살생물제에 대한 담체로서 나노입자의용도
EP1631259A4 (en) * 2002-12-18 2006-08-02 Hough Ear Inst OTOLOGICAL NANOTECHNOLOGY
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
EP2112196A1 (en) * 2008-04-25 2009-10-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO A liquid composition comprising polymer chains and particles of an inorganic material in a liquid
US20100098768A1 (en) * 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
JP2015518705A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
KR101415221B1 (ko) * 2012-08-07 2014-07-09 한국표준과학연구원 무기 나노입자를 유효성분으로 함유하는 혈관 신생 관련 질환의 예방 및 치료용 조성물
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CL2013003807A1 (es) * 2013-12-31 2014-07-11 Univ Santiago Chile Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol.
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3179982B1 (en) 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
WO2017007796A1 (en) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018053273A1 (en) 2016-09-15 2018-03-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Shear-thinning therapeutic composition, and related methods
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
MA51796A (fr) 2018-02-07 2020-12-16 Regeneron Pharma Procédés et compositions pour l'administration de protéines thérapeutiques
EP3788075A1 (en) 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
CN109045305B (zh) * 2018-07-31 2021-12-10 东华大学 一种tpgs修饰的锂皂石纳米颗粒的制备方法
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
EP3851097A1 (en) * 2020-01-15 2021-07-21 Universidad De Zaragoza Controlled release formulations
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
JPWO2022059736A1 (pt) 2020-09-17 2022-03-24
AU2021353913B2 (en) 2020-09-29 2024-11-07 President And Fellows Of Harvard College Stroke treatment
US20230220100A1 (en) 2022-01-10 2023-07-13 Regeneron Pharmaceuticals, Inc. Bbb-targeted gaa delivered as gene therapy treats cns and muscle in pompe disease model mice
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627124A (en) * 1899-06-20 Fan attachment for sewing-machines
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3884826A (en) * 1973-07-20 1975-05-20 Barnes Hind Pharm Inc Thixotropic cleaning agent for hard contact lenses
US3974125A (en) * 1974-09-27 1976-08-10 Exxon Research And Engineering Company Higher dialkyl dimethyl ammonium clay gelling agents for unsaturated polyester compositions
US4127423A (en) * 1977-09-13 1978-11-28 Burton, Parsons And Company, Inc. Contact lens cleaning solution
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4394179A (en) * 1979-06-25 1983-07-19 Polymer Technology Corporation Abrasive-containing contact lens cleaning materials
US4374745A (en) * 1981-08-13 1983-02-22 Barnes-Hind Pharmaceuticals, Inc. Cleaning compositions
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
EP0217440A1 (en) * 1985-09-27 1987-04-08 The Procter & Gamble Company Stable aqueous pharmaceutical suspensions
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
WO1988004168A1 (en) * 1986-12-08 1988-06-16 Arseco, Inc. A storage stable topical composition
US4847078A (en) * 1987-01-14 1989-07-11 Arseco, Inc. Storage stable topical composition having moisture control agent
BR8707615A (pt) 1986-12-24 1989-10-03 Alcon Lab Inc Composicao para limpeza de lentes de contato e processo para sua utilizacao
US4891043A (en) * 1987-05-28 1990-01-02 Board Of Trustees Of The University Of Illinois System for selective release of liposome encapsulated material via laser radiation
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5674504A (en) * 1989-07-12 1997-10-07 L'oreal Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP0546728A3 (en) * 1991-12-13 1993-09-08 Alcon Laboratories Inc Physiological tear compositions and methods for their preparation
US5139782A (en) * 1991-12-23 1992-08-18 Uop Facial cleansing mineral compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
ES2221921T3 (es) * 1992-07-13 2005-01-16 Shiseido Company, Ltd. Composicion para preparacion dermatologica.
US5532224A (en) * 1993-12-22 1996-07-02 Alcon Laboratories, Inc. Contact lens cleaning composition containing polyalklene oxide modified siloxanes
WO1996003158A1 (en) * 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
AU720326B2 (en) * 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6015816A (en) * 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
AU721273B2 (en) * 1996-09-20 2000-06-29 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US5811580A (en) * 1996-12-04 1998-09-22 The Lubrizol Corporation Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts
DK0948357T3 (da) * 1996-12-13 2002-07-15 Alcon Lab Inc Anvendelse af aminoalkoholer med lav molekylevægt i oftalmiske sammensætninger
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
CN1229110C (zh) * 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
BR9814180A (pt) 1997-11-12 2000-10-03 Bausch & Lomb Metodo e solucao para desinfetar e/ou limpar lentes de contato.
ZA9811445B (en) 1997-12-19 1999-08-16 Alcon Lab Inc Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
JPH11281937A (ja) 1998-03-27 1999-10-15 Menicon Co Ltd コンタクトレンズ用剤
US20010016577A1 (en) * 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
FR2783419B1 (fr) 1998-09-18 2002-07-12 Oreal Utilisation a ph acide de silicates mixtes en tant qu'agents tenseurs dans des compositions cosmetiques anti-rides
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6333054B1 (en) * 1999-10-21 2001-12-25 Amuchina S.P.A. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
JP2001240547A (ja) * 2000-02-29 2001-09-04 Lion Corp 花粉症抑制剤
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
BR0117090A (pt) 2001-08-02 2004-08-03 Johnson & Johnson Vision Care Lentes antimicrobianas e métodos de seu uso
PT1474109E (pt) 2001-12-21 2010-10-25 Alcon Inc Utilização de nanopartículas inorgânicas sintéticas como veículos em medicamentos oftálmicos
MXPA04004915A (es) * 2001-12-21 2004-08-11 Alcon Inc Nanoparticulas inorganicas para modificar la viscosidad y las propiedades fisicas de composiciones oftalmicas y oticas.
US7217853B2 (en) * 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
CN100369593C (zh) * 2002-06-05 2008-02-20 佛罗里达大学研究基金会有限公司 眼科给药体系
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
US20060193787A1 (en) * 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system

Also Published As

Publication number Publication date
WO2003059194A2 (en) 2003-07-24
HK1075001A1 (en) 2005-12-02
KR100990810B1 (ko) 2010-10-29
KR20040072669A (ko) 2004-08-18
US20050003014A1 (en) 2005-01-06
US8257745B2 (en) 2012-09-04
JP2005514429A (ja) 2005-05-19
CA2467763A1 (en) 2003-07-24
EP1474109A4 (en) 2006-03-29
ZA200403666B (en) 2005-07-27
PL211494B1 (pl) 2012-05-31
AU2002367029B2 (en) 2008-10-02
ES2349235T3 (es) 2010-12-29
DK1474109T3 (da) 2010-10-25
ATE478657T1 (de) 2010-09-15
AU2002367029A1 (en) 2003-07-30
CN100441169C (zh) 2008-12-10
CA2467763C (en) 2011-09-13
PL374262A1 (en) 2005-10-03
WO2003059194A3 (en) 2004-05-13
EP1474109A2 (en) 2004-11-10
US20110274760A1 (en) 2011-11-10
SI1474109T1 (sl) 2010-11-30
CN1604770A (zh) 2005-04-06
EP1474109B1 (en) 2010-08-25
PT1474109E (pt) 2010-10-25
DE60237475D1 (de) 2010-10-07
MXPA04004919A (es) 2004-08-11

Similar Documents

Publication Publication Date Title
BR0215238A (pt) Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas
BR0215149A (pt) Uso de nanopartìculas inorgânicas para modificar a viscosidade e outras propriedades fìsicas de composições farmacêuticas e óticas
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
BR9815570A (pt) Composto, processo de preparação dos compostos, utilização de pelo menos um composto, composição cosmética ou farmacêutica e utilização de pelos menos um polìmero
DE69725825D1 (de) 5-HT1F-Agonisten
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
ATE433996T1 (de) Humane dr4-antikörper und deren anwendungen
DE60231682D1 (de) Naturkautschuk-Masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
BG64475B1 (bg) Ципразидонови соли
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
BR0208741A (pt) Derivados de piperidina
BR0215176A (pt) Uso de nanopartìculas como veìculos para biocidas em composições oftálmicas
BR0207699A (pt) Produto para aplicação axilar
BR0007275A (pt) Naftopiranos e fenantropiranos anelados em c5-c6com um grupo bicìclico e composições e matrizes
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
WO2003015780A8 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
DE60233691D1 (de) Kosmetische Zusammensetzung mit einem Blockcopolymer
ID25478A (id) Agonis 5-ht1f
DK1232173T3 (da) Nye fusidinsyrederivater
BR0016168A (pt) Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
EP1132449A3 (en) Photochromic compounds in the solid state, process for their preparation and their use in polymeric materials
UA67058A (en) Composition for treating periodontitis
CY1109453T1 (el) Παραγωγα κινολινης και η χρηση τους στο γλαυκωμα και τη μυωπια

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.